What Is Liraglutide?
Liraglutide is a GLP-1 receptor agonist developed by Novo Nordisk — the same company behind semaglutide. It was approved in 2010 as Victoza for type 2 diabetes and in 2014 as Saxenda for chronic weight management. For several years, it was the clinical standard in GLP-1 therapy, demonstrating meaningful weight loss outcomes and cardiovascular benefits in large trials.
The fundamental limitation of liraglutide compared to semaglutide is pharmacological. Liraglutide is a daily injection. Semaglutide is a weekly injection. This difference alone substantially affects adherence — and adherence is the most important variable in long-term therapeutic outcomes. Beyond convenience, semaglutide also produces greater average weight loss.
How the Clinical Outcomes Compare
The SCALE trial for liraglutide 3 mg (Saxenda) showed average weight loss of approximately 5.4% of body weight at one year — with a higher-responder subset achieving 8 to 10%. The STEP 1 trial for semaglutide 2.4 mg showed 14.9% average weight loss over 68 weeks, with a large proportion of participants exceeding 15%.
This is not a marginal difference. The improvement in outcomes between liraglutide and semaglutide — using the same mechanism but a more durable, higher-exposure molecule — represents a clinical generation shift. The cardiovascular data for both drugs is strong, but semaglutide has now accumulated outcomes data across more patient populations and longer follow-up periods.
"Liraglutide represented a genuine clinical advance when it arrived. Semaglutide represented another one. This is what iterative drug development looks like when the mechanism is sound and the molecule can be optimized."
When Liraglutide Is Still Relevant
Liraglutide is not obsolete. There are patients for whom a daily injection schedule is actually preferable — some find daily micro-dosing easier to integrate than a weekly injection, particularly if they are already doing daily subcutaneous injections for other reasons. Liraglutide is also generically available in some markets, making it more accessible for patients who cannot afford semaglutide pricing.
For new patients starting a GLP-1 protocol today in the United States without significant cost constraints, semaglutide is the preferred starting point — better outcomes, better adherence profile, and comparable tolerability. The conversation about which drug to use is clinical. Cost, access, and individual history all factor into the right choice for a specific patient.
Compounded semaglutide — physician supervised.
503B sourced. Delivered to all 50 states.
What Comes After Semaglutide
Tirzepatide has already demonstrated better average weight loss outcomes than semaglutide. Retatrutide is producing Phase 2 data that exceeds both. The GLP-1 drug class is not standing still. The trajectory from exenatide to liraglutide to semaglutide to tirzepatide represents consistent, meaningful improvements with each generation — and the research pipeline suggests that trajectory continues.
Understanding where liraglutide fits helps contextualize how far the field has come and how to think about the options available today. For most patients, the relevant decision is between compounded semaglutide and tirzepatide — not whether to consider a drug that was the standard a decade ago.